



THE UNITED STATES PATENT AND TRADEMARK OFFICE

#60  
u.u.  
4/9/02

ATTY.'S DOCKET: KINOSHITA=3

Application of:	)	Art Unit: 1617
	)	
Shigeru KINOSHITA	)	Examiner: S.M.R. HUI
	)	
Serial No.: 09/623,138	)	Confirmation No. 9673
	)	
Filed: August 28, 2000	)	Washington D.C.
	)	
For: LANGERHANS CELL MIGRATION)	)	March 25, 2002
INHIBITORS	)	
	)	

**RECEIVED**  
MAR 29 2002  
TECH CENTER 1600/2900

AMENDMENT

Honorable Commissioner for Patents  
Washington, D.C. 20231

In response to the Office Action of  
November 23, 2001, for which a one month extension of  
time to respond is hereby requested, please enter the  
following amendment:

IN THE SPECIFICATION

Page 1, please amend the last paragraph lines  
26-28 through page 2 lines 1-4 as follows:

---

At present, potent drugs such as steroids and  
cyclosporin A are used to inhibit immunoreaction in the  
skin or cornea, but these drugs are inappropriate for use  
before inflammation occurs because of their various side  
effects. Therefore, there is a demand for development of  
a drug with less side effects that can be safely used  
before inflammation occurs.

---

In re Application of: Shigeru KINOSHITA  
 Serial No.: 09/623,138  
 Filed: August 28, 2000  
 For: LANGERHANS CELLS MIGRATION INHIBITORS



Art Unit: 1617  
 Confirmation No.: 9673  
 Examiner: S.M.R. HUI  
 Washington, D.C.  
 Atty.'s Docket: KINOSHITA=3  
 Date: March 25, 2002

1617  
 RECEIVED

MAR 29 2002

TECH CENTER 1600/2900

THE COMMISSIONER OF PATENTS AND TRADEMARKS  
 Washington, D.C. 20231

Sir:

Transmitted herewith is an [XX] Amendment [ ] \_\_\_\_\_  
 in the above-identified application.

- [ ] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.  
 [ ] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.  
 [ ] No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)		Small Entity		Other Than a Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For		Present Extra		Rate		Additional Fee
Total	6	Minus	20		0		x 9		\$
Indep.	1	Minus	3		0		x42		\$
First Presentation of Multiple Dependent Claim							140		\$
TOTAL ADDITIONAL CLAIMS FEE									\$
								Total	\$

- \* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.  
 \*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.  
 \*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.  
 The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time  
 If any extension of time for a response is required applicant requests that this be considered a petition therefor.

[XX] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- [ ] First - \$ 55.00  
 [ ] Second - \$200.00  
 [ ] Third - \$460.00  
 [ ] Fourth - \$720.00

Other Than Small Entity

Response Filed Within

- [XX] First - \$ 110.00  
 [ ] Second - \$ 400.00  
 [ ] Third - \$ 920.00  
 [ ] Fourth - \$1440.00

[ ] Less fees (\$ ) already paid for months extension of time on .

[ ] Please charge my Deposit Account No. 02-4035 in the amount of \$ . A duplicate copy of this sheet is attached.

[ ] A check in the amount of \$ is attached (check no. ).

[XX] Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$ 110.00 is attached.

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK  
 Attorneys for Applicant(s)

Facsimile: (202) 737-3528  
 Telephone: (202) 628-5197

By:   
 Anne M. Kornbau  
 Registration No. 25,884

AMK:nmp

F:\Y\YUAS\KINOSHITA3\PTO\cov1.wpd